Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)
Authors
Keywords
Gastric adenocarcinoma, S-1, Trastuzumab, Neuregulin1, First-line chemotherapy
Journal
Gastric Cancer
Volume 21, Issue 1, Pages 84-95
Publisher
Springer Nature
Online
2017-05-11
DOI
10.1007/s10120-017-0725-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK)
- (2016) Mayuko Saito et al. ACTA ONCOLOGICA
- Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?
- (2016) Takeshi Yamada et al. JOURNAL OF GASTROENTEROLOGY
- Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)
- (2015) M.-H. Ryu et al. ANNALS OF ONCOLOGY
- Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy
- (2015) Jun Zhou et al. JOURNAL OF GASTROENTEROLOGY
- Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients
- (2014) Zhi Peng et al. Biomarkers in Medicine
- Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)
- (2014) Y Kurokawa et al. BRITISH JOURNAL OF CANCER
- Evaluation of serum HER2-ECD levels in patients with gastric cancer
- (2014) Katsunobu Oyama et al. JOURNAL OF GASTROENTEROLOGY
- Overexpression of NRG1 promotes progression of gastric cancer by regulating the self-renewal of cancer stem cells
- (2014) Myoung-Eun Han et al. JOURNAL OF GASTROENTEROLOGY
- Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study
- (2012) Kensei Yamaguchi et al. Gastric Cancer
- Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
- (2011) Akira Sawaki et al. Gastric Cancer
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Study of inhibition effect of Herceptin on interaction between Heregulin and ErbB Receptors HER3/HER2 by single-molecule force spectroscopy
- (2009) Xiaoli Shi et al. EXPERIMENTAL CELL RESEARCH
- Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
- (2008) D. L. Shattuck et al. CANCER RESEARCH
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
- (2008) Wasaburo Koizumi et al. LANCET ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started